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Abstract
Background: Epidemiological data on Acute Kidney Injury (AKI) from low-income countries is sparse. The aim of
this study was to establish the incidence, severity, aetiology, and outcomes of community-acquired AKI in Malawi.
Methods: We conducted a prospective observational study of general medical admissions to a tertiary hospital in
Blantyre between 27th April and 17th July 2015. All patients were screened on admission with a serum creatinine;
those with creatinine above laboratory reference range were managed by the nephrology team. Hospital outcome
was recorded in all patients.
Results: Eight hundred ninety-two patients were included; 188 (21 · 1%) had kidney disease on admission, including
153 (17 · 2%) with AKI (median age 41 years; 58 · 8% HIV seropositive). 60 · 8% of AKI was stage 3. The primary causes
of AKI were sepsis and hypovolaemia in 133 (86 · 9%) cases, most commonly gastroenteritis (n = 29; 19 · 0%) and
tuberculosis (n = 18; 11 · 8%). AKI was multifactorial in 117 (76 · 5%) patients; nephrotoxins were implicated in 110
(71 · 9%). Inpatient mortality was 44 · 4% in patients with AKI and 13 · 9% if no kidney disease (p <0.0001). 63 · 2% of
patients who recovered kidney function left hospital with persistent kidney injury.
Conclusion: AKI incidence is 17 · 2% in medical admissions in Malawi, the majority is severe, and AKI leads to
significantly increased in-hospital mortality. The predominant causes are infection and toxin related, both potentially
avoidable and treatable relatively simply. Effective interventions are urgently required to reduce preventable young
deaths from AKI in this part of the world.
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Background
Acute Kidney Injury (AKI) refers to a rapid worsening
or loss of kidney function caused by a variety of different
mechanisms. Most epidemiological data on AKI comes
from developed world settings. Here, AKI is predomin-
antly hospital acquired, affecting up to 22% of adult pa-
tients during an inpatient stay [1, 2]. It leads to adverse
outcomes for individuals, even in its mildest forms, with
mortality across all stages of AKI estimated at 21%, in-
creasing with AKI severity [2, 3]. Moreover, it can lead
to other organ dysfunction and the development or pro-
gression of chronic kidney disease (CKD) [4].
Whilst unknown, the potential global burden of AKI is
vast. 85% of the world’s population lives in developing
world settings and assuming the same incidence and
outcome of AKI to high-income countries, this equates
to an estimated 13 · 3 million cases of AKI per year
worldwide, resulting in a potential 1 · 7 million deaths
[5]. The greatest impact of AKI may therefore be in the
poorest parts of the world. It is in these regions, however,
where epidemiological data on AKI is most limited and
where adverse outcomes from AKI may be preventable
with relatively cheap and simple interventions [6, 7].
The International Society of Nephrology (ISN) launched
the 0by25 initiative in response to this concern about a
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significant burden of undiagnosed and untreated AKI in
resource poor areas [2]. The initiative aims to eliminate
preventable deaths from AKI by 2025. One of its key ini-
tial goals is to collect epidemiological data on AKI and its
outcomes, especially in low-income settings. This is an es-
sential first step in attempts to improve management of
AKI and its consequences worldwide.
The aim of this study was to determine the incidence,
severity, aetiology, and outcomes of community-acquired
AKI (com-AKI) in general medical admissions at a tertiary
hospital in Malawi, a resource-poor country in sub-Sahara
Africa.
Methods
Study design and setting
We conducted a prospective, observational study at Queen
Elizabeth Central Hospital (QECH), Blantyre, Malawi.
Government healthcare, although resource-limited, is free
at the point of delivery, including widespread access to
antiretroviral therapy (ART) for patients with HIV.
Blantyre is the second largest city in Malawi and QECH
acts as both a district and a regional hospital, although
the majority of patients admitted are from Blantyre dis-
trict itself, population approximately 1 million [8]. Around
15 medical patients are admitted per day and medications
to manage common causes of sepsis (broad spectrum an-
tibiotics, anti-malarials and anti-tuberculous drugs) are
usually available. QECH acts as the nephrology referral
centre for the southern region including free provision of
haemodialysis to patients with AKI and to a limited cohort
with end stage kidney disease.
Participants
Patients were enrolled between a pre-specified consecu-
tive 12-week time period, 27th April-17th July 2015. All
medical admissions ≥14 years (local age cut off for ad-
mission under adult medicine) were included. Patients
unable to consent or transferred to the medical service
from another specialty ward or hospital were excluded.
Data collection
Baseline demographic and clinical data were collected in
all patients and screening for AKI undertaken with a
serum creatinine. Data was obtained from the patient’s
medical record; the admission diagnosis was that docu-
mented by the admitting physician.
Patients with an admission creatinine above the labora-
tory reference range (>90 μmol/L in women; >104 μmol/L
in men) were reviewed daily and managed by the nephrol-
ogy team. Urine output was recorded and the creatinine
was reassessed at 24 h (day 1) and then every 48 h until
death in hospital or discharge. We documented the nature
and most likely cause of renal impairment based on the
assessment of all available clinical and laboratory investi-
gations as well as details of management thereafter.
Patients with a normal admission creatinine were man-
aged by general medical physicians and not routinely seen
by the study team. These patients did not have creatinine
repeated by the study team and the development of AKI
in hospital was not assessed. Length of stay and hospital
outcome (discharge or death) was recorded in all patients.
If a patient was admitted more than once during the study
period, each admission was treated as a new case.
Definition of AKI
AKI and its staging, Acute Kidney Disease (AKD) without
AKI, and CKD were defined by Kidney Disease Improving
Global Outcomes (KDIGO) criteria (Additional file 1
Table S1). Patients not fulfilling these criteria were
deemed as having no kidney disease (NKD). Community-
acquired AKI (com-AKI) is AKI that is detected at, or
within 48 h, of hospital admission.
AKI aetiology was categorized by Acute Kidney Injury
Network (AKIN) criteria: Sepsis and hypoperfusion, Toxins,
Obstruction, and Parenchymal kidney disease (STOP) [9].
The discharge creatinine was the last creatinine measured
as an inpatient. Renal recovery was pre-defined by our own
definition as partial if the discharge creatinine was >10%
below the peak value, and complete if within the laboratory
reference range, or within 10% of a previously known
baseline value.
Creatinine measurement
Creatinine was measured by Jaffe method [either by Flexor
Junior Clinical Chemistry Analyzer (Vital Scientific,
Dieren, The Netherlands) or by Mindray Chemistry
Analyzer BS-120 (Shenzen Mindray Bio-Medical Elec-
tronics Company, Shenzen, China)] in a local labora-
tory. A second analyser was used due to unresolvable
technical problems with the original machine during
part of the study. Both machines were calibrated ac-
cording to the manufacturer’s instructions.
Outcome measures
Primary outcome measures were the incidence propor-
tion of com-AKI, the aetiology of AKI, and the effect of
AKI on in-hospital mortality. Secondary outcomes were
the severity of AKI, an evaluation of the independent
risk factors for the presence of AKI on admission and
death from AKI, in addition to an assessment of renal
recovery from AKI. Given the high prevalence of HIV in
medical admissions, we also evaluated the aetiology and
outcomes from AKI in patients with HIV.
Statistical analysis
We compared variables between patients with NKD, any
stage of AKI, stage 1 or 2 AKI and stage 3 AKI using
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standard parametric, non-parametric and Chi2 tests ac-
cording to the distribution of variables. We combined
patients with stage 1 or 2 AKI into a single group, given
the relatively small number of patients with less severe
AKI.
We performed a survival analysis, comparing patients
with NKD, stage 1 or 2 AKI and stage 3 AKI, using the
log rank test to examine for differences in survival be-
tween these groups. This analysis was censored at 15 days
since the number at risk in each group reduced dramatic-
ally at this point (<10 in both AKI groups). We calculated
crude and adjusted hazard ratios for mortality, adjusting
for a priori confounding variables of age (< or >40 years)
and sex, as well as variables associated with AKI develop-
ment and mortality in univariate analyses with a pre-
defined p value for addition into the model of <0 · 05. For
this analysis, we excluded patients who were alive and still
inpatients at the end of the pre-specified study period.
We used a logistic regression model with forward fit-
ting of variables to identify the independent risk factors
for any stage of AKI on admission including in the
model risk factors most strongly associated with AKI in
a univariate analysis with a p value of <0 · 05 for entry in
to the model. In a subgroup analysis, we compared pa-
tients with AKI who were HIV positive to those who
were HIV negative or unknown.
All analyses were conducted using Stata v 10 with a
p value of <0 · 05 considered to be statistically significant.
Results
Participants
943 patients were admitted under general medicine
during the study period and 892 were enrolled (Fig. 1).
Descriptive data
Baseline characteristics are outlined in Table 1. The me-
dian age was 37 years (interquartile range [IQR] 30–52),
391 (43 · 8%) patients had HIV and 109 (12 · 2%) had
pre-existing hypertension, but other co-morbidities were
relatively uncommon. 324 (36 · 3%) patients were taking
ART, 311 (34 · 9%) tenofovir (TDF) based.
Increased age, HIV seropositivity, a history of previous
tuberculosis (TB), diabetes melllitus (DM), or known
CKD, and TDF use were all more prevalent in patients
with any stage of AKI. Most admissions were due to in-
fective illnesses. An admission diagnosis of gastroenteritis
(GE), acute TB, and liver failure were significantly more
common in patients with AKI (Table 1).
Outcome data
AKI Incidence proportion in the study population
Of 892 patients enrolled, 188 (21 · 1%) had evidence of
kidney disease (Fig. 1). 153 (17 · 2%) patients had AKI,
29 (3 · 3%) had AKD without AKI, and 6 patients (0 · 6%)
had established stable CKD. Of those with AKI, the max-
imum stage was stage 1 in 33 (21 · 6%) patients, stage 2 in
27 (17 · 7%) patients, and stage 3 in 93 (60 · 8%) patients.
The median presenting creatinine values in patients
with Stage 1,2 and 3 AKI was 140 μmol/L (124–159),
212 μmol/L (157–297), and 565 μmol/L (327–878)
respectively.
51 (6 · 0%) patients (9 AKI; 42 NKD) remained in hos-
pital at the end of the study and were excluded from the
outcome analysis.
AKI Aetiology
The primary causes of AKI are outlined in Table 2. In 117
(76 · 5%) patients, AKI was multifactorial. Nephrotoxins as
Fig. 1 Patient enrollment, incidence and severity of AKI
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a contributing factor, as opposed to the primary cause,
were implicated in 110 (71 · 9%) cases of AKI. The most
common nephrotoxins implicated were tenofovir based
antiretroviral therapy (TDF ART) (n = 61; 40 · 0%) and
non-steroidal anti-inflammatory drugs (NSAIDs) (n = 53;
34 · 6%). Traditional or herbal remedies had been taken by
12 (7 · 8%) patients with AKI prior to admission.
Cases of AKI treated with haemodialysis
Renal replacement therapy was indicated in 21 (13 · 7%)
patients with AKI; acute haemodialysis was provided in
8 (38 · 1%). Reasons for not providing dialysis were clin-
ician judgement of medical futility (n = 9), haemodynamic
instability precluding haemodialysis (n = 3), and logistical
reasons (n = 1). The primary causes of AKI in patients that
underwent haemodialysis were: falciparum malaria (n = 4),
post-infective (malaria) glomerulonephritis (n = 1), ty-
phoid (n = 1), non-typhoid salmonella (n = 1), and multiple
drug toxicity (n = 1). Median number of sessions was 4
(3 · 5–6). Renal recovery (dialysis independence) occurred
in 6 (75%) patients, dialysis was withdrawn in one patient,
and one patient died while being actively treated.
Table 1 Baseline data in all patients in the study population, in patients with no kidney disease (NKD), and in patients with Acute
Kidney Injury (AKI). Variables are compared between NKD and AKI
Demographic Variable All patients N = 892 No Kidney Disease (NKD) N = 704 Acute Kidney Injury (AKI) N = 153 P value
Age (median; IQR) 37 (30–52) 36 (28–50) 41 (32–58) 0 · 0008
Male sex 500 (56 · 1%) 388 (55 · 1%) 92 (60 · 1%) 0 · 257
Medical History
HIV 391 (43 · 8%) 281 (39 · 9%) 90 (58 · 8%) <0 · 0001
HTN 109 (12 · 2%) 78 (11 · 1%) 24 (15 · 7%) 0 · 112
CVDa 52 (5 · 8%) 39 (5 · 6%) 12 (7 · 8%) 0 · 277
TB 43 (4 · 8%) 28 (4 · 0%) 15 (9 · 8%) 0 · 003
DM 34 (3 · 8%) 20 (2 · 9%) 10 (6 · 5%) 0 · 025
Liver Disease 8 (0 · 9%) 5 (0 · 7%) 3 (2 · 0%) 0 · 145
Malignancy 7 (0 · 8%) 3 (0 · 4%) 3 (2 · 0%) 0 · 48
Known CKD 5 (0 · 6%) 0 (0%) 2 (1 · 3%) 0 · 027
Medications
NSAID 339 (38 · 1%) 259 (37 · 0%) 66 (43 · 1%) 0 · 153
TDF ART 311 (34 · 9%) 234 (33 · 2%) 66 (43 · 1%) 0 · 02
Diuretic 144 (16 · 2%) 109 (15 · 5%) 26 (17 · 0%) 0 · 652
ACEi or ARB 31 (3 · 5%) 19 (2 · 7%) 6 (3 · 9%) 0 · 419
Non TDF ART 13 (1 · 5%) 3 (0 · 4%) 6 (3 · 9%) 0 · 001
Admission Diagnosis
LRTI 215 (24 · 1%) 196 (27 · 8%) 16 (10 · 4%) <0 · 0001
Sepsisb unclear source 104 (11 · 6%) 81 (11 · 5%) 21 (13 · 7%) 0 · 442
GE 79 (8 · 9%) 46 (6 · 5%) 30 (19 · 6%) <0 · 0001
Meningitis 66 (7 · 4%) 61 (8 · 7%) 5 (3 · 3%) 0 · 023
Stroke 63 (7 · 1%) 51 (7 · 2%) 8 (5 · 2%) 0 · 37
Heart Failure 62 (7 · 0%) 45 (6 · 4%) 13 (8 · 5%) 0 · 348
Symptomatic Anaemia 60 (6 · 7%) 45 (6 · 4%) 11 (7 · 2%) 0 · 718
TB 43 (4 · 8%) 28 (4 · 0%) 15 (9 · 8%) 0 · 003
Malaria 33 (3 · 7%) 21 (3 · 0%) 9 (5 · 9%) 0 · 077
Liver failure 26 (2 · 9%) 14 (2 · 0%) 11 (7 · 2%) 0 · 001
Disseminated malignancy 17 (1 · 9%) 14 (2 · 0%) 3 (2 · 0%) 0 · 982
Other 124 (13 · 9%) 102 (14 · 5%) 11 (7 · 2%) 0 · 45
AKI acute kidney injury, HIV human immunodeficiency virus, HTN hypertension, CVD cardiovascular disease, TB tuberculosis, DM diabetes mellitus CKD chronic
kidney disease, NSAID non steroidal anti-inflammatory drug, TDF ART tenofovir based antiretroviral therapy, ACEi angiotensin converting enzyme inhibitor,
ARB angiotensin receptor blocker, LRTI lower respiratory tract infection (including pleural effusion), GE gastroenteritis
aischaemic heart disease, cerebrovascular disease, or peripheral vascular disease
bclinical diagnosis
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In-hospital mortality
Crude inpatient mortality was 44 · 4% (n = 64) in patients
with AKI compared with 13 · 9% (n = 92) in patients with
no kidney disease (p <0 · 0001). Crude mortality in pa-
tients with AKI was higher with increasing AKI severity
[n = 18 (30 · 0%) in stage 1 and 2 vs. n = 46 (49 · 5%) in
stage 3; p = 0 · 017].
In a survival analysis, patients with stage 3 AKI had
significantly higher in-hospital mortality than patients
with either NKD or stage 1 or 2 AKI (chi2 test 59.4; log
rank test p <0 · 0001, Fig. 2). Crude hazard ratios (95%
confidence interval) for mortality comparing patients
with stage 1 or 2 AKI and stage 3 AKI to patients with
NKD were 2 · 33 (1 · 40–3 · 87, p = 0 · 001) and 3 · 68 (2 ·
57–5 · 27, p <0 · 0001) respectively. Hazard ratios for
mortality compared to NKD adjusted for age, sex, use
of any toxin and HIV status were 2 · 14 (1 · 27–3 · 59, p =
0 · 004) for stage 1 or 2 AKI and 3 · 37 (2 · 32–4 · 89, p
<0 · 0001) for stage 3 AKI.
Table 2 Primary Causes of Acute Kidney Injury (AKI) in patients with any stage of AKI, stage 1 or 2 AKI, and stage 3 AKI
Primary cause of AKI AKI all (n = 153) AKI stage 1 or 2 (n = 60) AKI stage 3 (n = 93)
Sepsis and hypoperfusion 133 (86 · 9%) 55 (91 · 7%) 78 (83 · 9%)
GEa 29 (19 · 0%) 12 (20 · 0%) 17 (18 · 3%)
TB 18 (11 · 8%) 5 (8 · 3%) 13 (14 · 0%)
Heart failure 16 (10 · 5%) 10 (16 · 7%) 6 (6 · 5%)
Malaria 12 (7 · 8%) 4 (6 · 7%) 8 (8 · 6%)
Dehydration of other cause 12 (7 · 8%) 6 (10 · 0%) 6 (6 · 5%)
LRTI 10 (6 · 5%) 6 (10 · 0%) 4 (4 · 3%)
Sepsis of unclear source 9 (5 · 9%) 2 (3 · 3%) 7 (7 · 5%)
Liver Failure 8 (5 · 2%) 3 (5 · 0%) 5 (5 · 4%)
Meningitis 7 (4 · 6%) 4 (6 · 7%) 3 (3 · 2%)
Sepsis of other known source 4 (2 · 6%) 1 (1 · 7%) 3 (3 · 2%)
UTI 1 (0 · 7%) 0 (0 · 0%) 1 (1 · 1%)
Other 7 (4 · 6%) 2 (3 · 3%) 5 (5 · 4%)
Toxin (as primary cause) 5 (3 · 3%) 3 (5 · 0%) 2 (2 · 1%)
NSAID 4 (2 · 6%) 3 (5 · 0%) 1 (1 · 1%)
ACEi or ARB 1 (0 · 7%) 0 (0 · 0%) 1 (1 · 1%)
Urinary tract Obstruction 7 (4 · 6%) 1 (1 · 6%) 6 (6 · 5%)
Prostate disease 2 (1 · 3%) 0 (0 · 0%) 2 (2 · 2%)
Cervical malignancy 1 (0 · 7%) 0 (0 · 0%) 1 (1 · 1%)
Bladder Malignancy 1 (0 · 7%) 0 (0 · 0%) 1 (1 · 1%)
Unclear/other 3 (2 · 0%) 1 (1 · 7%) 2 (2 · 2%)
Parenchymal Kidney disease 4 (2 · 6%) 0 (0 · 0%) 4 (4 · 3%)
Acute GN 3 (2 · 0%) 0 (0 · 0%) 3 (3 · 3%)
TIN (presumed) 1 (0 · 7%) 0 (0 · 0%) 1 (1 · 1%)
Unclear 4 (2 · 6%) 1 (1 · 7%) 3 (3 · 2%)
AKI acute kidney injury, GE gastroenteritis, TB tuberculosis, LRTI lower respiratory tract infection (including pleural effusion), UTI urinary tract infection, NSAID non
steroidal anti-inflammatory drug, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, TDF ART tenofovir based antiretroviral therapy,
GN glomerulonephritis, TIN tubulointerstitial nephritis
aincluding typhoid and non-typhoidal salmonella
Fig. 2 Kaplan-Meier analysis demonstrating survival probability in
patients with No Kidney Disease (NKD), AKI stage 1 or 2, and AKI stage 3
up to 15 days. 137 (87 · 8%) of 156 deaths occurred before or on day 15.
Patients have been censored for hospital discharge, as follow up was
not undertaken after discharge to assess for out of hospital mortality
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Independent risk factors for developing any stage of
AKI were age >40 years (p = 0 · 0001), HIV seropositivity
(p <0 · 0001), underlying DM (p = 0 · 01), presentation
with GE (p <0 · 0001), liver failure (p = 0 · 0002) or TB
(p = 0 · 0034), and the use of any nephrotoxin prior to
admission (p = 0 · 04).
Independent risk factors for in-hospital mortality in
patients with AKI were stage of AKI (stage 3 vs. stage 1
or 2; p = 0 · 016), age >40 (p = 0 · 02), and use of any
nephrotoxin (p = 0 · 04).
Renal recovery
Some degree of renal recovery was evident by discharge in
68 (47 · 2%) patients with AKI. Any degree of renal recov-
ery was more likely in stage 1 and 2 compared to stage 3
AKI [n = 35 (65 · 0%) vs. n = 33 (38 · 8%), p = 0 · 002]. If
renal recovery occurred, persistent kidney injury was
present at discharge in 43 (63 · 2%) AKI patients overall,
17 (48 · 6%) if AKI stage 1 or 2, and 26 (78 · 0%) if AKI
stage 3 (p = 0 · 01). The median creatinine in AKI survi-
vors at hospital discharge was 129 μmol/L (114–167),
126 μmol/L (97–215), and 552 μmol/L (324–921) in
stages 1,2 and 3 respectively.
Median length of hospital stay was longer in any stage of
AKI (7 · 5 days; 5–12) compared with NKD (6 days; 4–10)
but this did not reach statistical significance (p = 0 · 052).
HIV subgroup analysis
The characteristics of patients with AKI comparing HIV
status are summarised in Table 3. Patients with HIV
were younger. There were no significant differences in
AKIN aetiological categories of AKI (Sepsis and hypo-
perfusion, Toxins, Obstruction and Parenchymal Kidney
Disease [STOP]), AKI severity, mortality, length of stay
or renal recovery between patients with HIV and those
without HIV or in whom HIV status was unknown.
Discussion
This is the first study to prospectively determine the in-
cidence, aetiology, severity and outcomes of com-AKI in
an unselected patient cohort in sub-Sahara Africa (SSA).
AKI is common, serious and treatable in the developed
world. Estimates of incidence based on developed world
data suggest an undiagnosed epidemic in less developed
countries, and reports of deficiencies in care raise the
concept that young lives are being unnecessarily lost [2].
However, particularly in SSA, data to corroborate these
hypotheses are sparse. We therefore undertook this real-
life, pragmatic study to understand the current epidemi-
ology of AKI in Malawi.
Key results
We have demonstrated that com-AKI is both common
and severe in medical admissions in Malawi. 17 · 2% of
patients had established AKI on admission over the 3-
month data collection period; 10 · 5% of general medical
admissions had stage 3 AKI. Patients were young, from
an economically viable section of the population, and
HIV prevalence was high, particularly in patients with
AKI.
Table 3 Comparison of AKI in patients with HIV to patients without HIV or in whom HIV status was unknown
No HIV or HIV unknown (n = 63) HIV (n = 90) P value
Demographics
Age (median; IQR) 53 (35–71) 38 (32–46) 0 · 0004
Male sex 35 (55 · 6%) 57 (63 · 3%) 0 · 334
Primary cause of AKI
Sepsis and hypoperfusion 51 (80 · 1%) 82 (91 · 1%) 0 · 058a
Toxin 1 (1 · 6%) 4 (4 · 4%)
Obstruction 6 (9 · 5%) 1 (1 · 1%)
Parenchymal Kidney disease 2 (3 · 2%) 2 (2 · 2%)
Unclear 3 (4 · 8%) 1 (1 · 1%)
AKI Severity
AKI Stage 3 39 (61 · 9%) 54 (60 · 0%) 0 · 81
Outcomes
In-hospital mortality 22 (37 · 9%) 42 (48 · 4%) 0 · 20
Length of stay in days (median; IQR) 7 · 5 (4–13) 7 · 5 (5–11) 0 · 74
Renal recovery (any) 27 (49 · 1%) 41 (49 · 4%) 0 · 97
Persistent kidney injury at dischargeb 19 (70 · 4%) 24 (58 · 4%) 0 · 32
AKI acute kidney injury, HIV human immunodeficiency virus
aChi2 test assessing the association of the aetiological category of AKI between groups
bexpressed as a proportion of those with any renal recovery
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The predominant aetiological category of AKI was
Sepsis/hypoperfusion, encompassing conditions that are
amenable to early identification and effective treatments
routinely available across much of SSA. The most com-
mon infections were GE, acute TB, and falciparum
malaria.
Hospital outcomes in patients with AKI were poor and
these worsened with AKI stage. Hospital mortality was
44 · 4% in patients with AKI overall and almost half of
patients with stage 3 AKI died. The majority of patients
with AKI who survived left hospital with persistent and
severe renal injury, particularly patients with stage 3 AKI.
Interpretation
AKI affects 1 in 5 inpatients in developed settings [2],
but the majority is mild and hospital-acquired [10].
Com-AKI is less common, with incidence estimates of
4 · 3% in the UK [11], whereas in SSA com-AKI predom-
inates [6, 7, 12].
Rates of com-AKI in this study were more than quad-
ruple what is seen in developed settings (Additional file 2
Table S2). Moreover the kidney injury was predominantly
severe (stage 3 in 60 · 5%) as opposed to the mild pattern
of AKI seen in developed settings (stage 1 in 80%) [2].
This burden and severity of AKI is likely multifactorial in
nature. Delayed referral to hospital due to limited aware-
ness of kidney injury and the resources to detect it in
health centres and district hospitals [13, 14], logistical and
financial challenges transporting patients to hospital, an
admission cohort primed for AKI in terms of co-
morbidity (high HIV prevalence), community nephrotoxin
use, and severe acute presenting illness all contribute.
Data from SSA with which to compare these incidence
and severity estimates is limited [7]. The rate of AKI in
the two previous prospective studies in medical cohorts
in SSA were similar to ours: 16% in 387 patients pre-
senting with sepsis in urban Uganda and 15 · 2% in 151
medical inpatients in rural Ethiopia [15, 16]. The majority
of AKI was severe in both, with 46-48% of AKI stage 3.
The age of patients with AKI in our study is similar to
findings from other studies from SSA, where mean ages
of patients with AKI have ranged from 28 · 7–44 · 4 years
[7]. Patients are around 20 years younger than AKI co-
horts in developed settings [10].
The prevalence rate of HIV is approximately 10% in
15–49 year-olds in the general population in Malawi
[17]. Patients with HIV were disproportionately repre-
sented in the medical admission cohort as a whole, but
particularly so if presenting with AKI. 58 · 8% of patients
with AKI had HIV; similar rates have been recently re-
ported in other SSA AKI cohorts [15]. HIV may increase
the risk of AKI through direct renal injury, through ART
nephrotoxicity, and through susceptibility to acute in-
fective illness. Routine measurement of renal function
pre or post initiation of TDF ART (first-line in adults) is
not recommended in Malawi despite the potential
nephrotoxic effects of TDF [18], which may delay diag-
nosis of AKI in this cohort. Importantly, AKI in Malawi
is occurring in patients that are young with limited co-
morbidity outside HIV. Such patients are often respon-
sible for the social and financial stability of extended
families and thereby the impact of AKI extends beyond
the individual.
Medical causes of AKI predominate in SSA and, simi-
lar to previous data, AKI in this study was largely due to
infective illnesses [6, 7]. Microbiological causes of GE
were rarely identified, as faecal microbiology is not rou-
tinely undertaken. Typhoid and non-typhoid salmonella
bacteraemia did, in some cases, present with diarrhoeal
illness. Despite this study occurring outside malaria sea-
son, it remained a common cause of AKI. Acute decom-
pensated heart failure was the commonest cause of renal
hypoperfusion outside infective illness, and this was par-
ticularly prevalent in the non-HIV AKI group.
In addition to infection, nephrotoxins (in particular
NSAIDs) were the other main contributors to AKI. The
crucial significance of these causes and contributors is
that it suggests the majority of this AKI is preventable
and treatable by relatively simple means such as early
fluid resuscitation, treatment of the underlying condition,
and avoidance of nephrotoxic drugs. These are universally
achievable interventions that don’t require sophisticated
diagnostic techniques or expensive treatments. Despite
this, deficiencies in resources and skills to manage even
these basic aspects of AKI across SSA persist [13, 14].
The worldwide pooled mortality from AKI is 21% [2]
and this rises to 32% in studies undertaken in SSA [7].
In-hospital mortality in this study was almost double
worldwide estimates. Mortality increased with AKI stage,
49 · 5% in stage 3 AKI, a closer reflection of the worldwide
mortality of 42% seen at this stage of disease. In part, the
high overall mortality reflects the severity of AKI en-
countered in this setting but may also relate to lack of
resources to manage underlying conditions, in particu-
lar severe sepsis.
Some form of renal recovery occurred in the majority
of adult survivors although this recovery was largely in-
complete. This may represent patients with resolving
AKI, undiagnosed or de novo CKD, and highlights the
need for follow up and assessment of longer-term out-
comes post AKI, especially in this part of the world. Recur-
rent, severe AKI in SSA may contribute to the growing
burden of CKD in this setting [19].
Taken together, the mortality and persistent renal in-
jury seen in this study are concerning. Moreover, the
outcomes in this study, whilst poor, were achieved in a
clinical research environment in which all patients had
immediate assessment of renal function, management by
Evans et al. BMC Nephrology  (2017) 18:21 Page 7 of 9
a nephrologist, and free access to renal replacement
therapy (RRT). This is not the case during routine clin-
ical practice across SSA. The poor outcomes therefore
represent, in our view, a “best-case scenario” for SSA
and highlight the urgency with which we as a global
healthcare community must improve AKI detection and
management in resource poor settings worldwide.
Strengths and limitations
Most studies investigating AKI in SSA are retrospective
case series, often focusing on patients that present re-
quiring RRT or on a single cause of AKI (Additional file
3 Table S3). There has been no previous prospective
study in SSA that we are aware of in which an unse-
lected medical admission cohort has been screened for
com-AKI. This is important as laboratory assessment of
renal function is not routine in SSA and therefore only
through this approach can the frequency, severity and
outcomes of com-AKI be accurately determined. Our
study is the first to do this in SSA, screening 892 pa-
tients, and the 153 patients with com-AKI identified rep-
resents the largest prospective AKI cohort reported from
this region of the world.
This was a single centre study conducted during a sin-
gle season of the year in medical admissions only. This
study focused on community acquired AKI and the de-
velopment of AKI in hospital was not assessed. Lack of
known baseline creatinines in almost all patients and
practical challenges in collecting urine output data (e.g.
lack of urine measuring jugs, lack of catheter bags with
graduations to accurately measure urine volume) may
have resulted in some patients with AKI being classified
as AKD, underestimating the true incidence. Unresolv-
able technical problems with the creatinine analyser
meant a second machine had to be used for part of the
study and consequently no data is available to assess any
assay variability between the different machines. It is un-
likely this resulted in any significant misclassification of
stage of AKI and whilst we recognise that this is a limi-
tation of the study, the situation represents the real-life
pragmatic challenges related to research conducted in
this and similar settings. Resource restrictions meant
supporting diagnostics were limited and causes of AKI
were based largely on clinical assessment but this is re-
flective of standard clinical practice across much of SSA.
Hospital outcome was captured in all patients, but lon-
ger follow up thereafter was not.
Our aim, and that of the International Society of
Nephrology 0by25 Initiative, is to investigate AKI in
low-income settings. Malawi ranks as one of the poorest
countries in the world [20] and therefore this study re-
flects AKI in a truly low-income setting. This study was
undertaken in a centre which serves both urban and
rural populations. Healthcare is provided free at the
point of delivery and therefore the population repre-
sented in this study is not influenced by financial factors
limiting access to care. We are sanguine about the fact
that many other neighbouring healthcare systems levy a
charge for even basic interventions including intraven-
ous fluids and antibiotics. Thus, our study may not be
generalisable to these settings, where outcomes from
AKI may be even worse.
Conclusions
Com-AKI incidence is 17 · 2% in medical admissions in
Malawi, the majority is severe, and AKI leads to signifi-
cantly increased in-hospital mortality. Sepsis, hypovol-
aemia related to sepsis, and toxins are the predominant
causes. As simple treatments are often available, earlier
identification of AKI is essential both in hospital and at
lower tiers of the healthcare system, and resource should
be concentrated on education programmes and point of
care tests to improve this. A study of the effect of a sim-
ple intervention can then be done to assess its impact
on mortality as part of attempts to reduce preventable
deaths from AKI in this part of the world.
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